Deferasirox

Evidence Level: L4

Predicted Indications: 5

Deferasirox

Pharmacist Assessment Report

Deferasirox: From Beta-Thalassemia (Iron Overload) to HIV Infectious Disease

One-Sentence Summary

Deferasirox is an oral iron chelator, originally used for iron overload in beta-thalassemia and related hemoglobinopathies. The TxGNN model predicts it may be effective for HIV infectious disease, but no clinical trials are registered, and only 2 publications are available, of which just 1 is a preclinical study with an indirect link. This is a model-driven hypothesis at an early research stage.

Quick Overview

Item	Content
Original Indication	Beta-thalassemia and related hemoglobinopathies (hereditary persistence of fetal hemoglobin, beta-thalassemia intermedia, hemoglobinopathy); no approved indication text is available in the India licence records
Predicted New Indication	HIV infectious disease
TxGNN Prediction Score	0.9940
Evidence Level	L4
India Market Status	Listed in a compiled Indian medicine price dataset (16 of 16) – CDSCO approval status is not included in this data
Number of Listed Products	16 (valid: 16)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, deferasirox is an oral iron chelator, its use in iron overload from beta-thalassemia and related conditions is established, and mechanistically it may be applicable to HIV infection through iron’s role in the viral life cycle.

A 2021 preclinical study (PMID 34550543) reports that iron in endolysosomes restricts Tat-mediated HIV-1 LTR transactivation, by increasing Tat oligomerization and β-catenin expression. This suggests iron homeostasis can influence HIV-1 transcription, which gives a plausible but indirect reason for the prediction.

There are important caveats. The study examines iron’s role in the virus life cycle and does not test deferasirox in HIV patients. Iron chelation could also have opposing effects, for example by altering host immune function, so the direction of any benefit is unestablished.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34550543	2021	Preclinical/Mechanistic	Journal of Neurovirology	Endolysosomal iron restricts Tat-mediated HIV-1 LTR transactivation by increasing Tat oligomerization and β-catenin expression
16529348	2006	Review	Journal of the American Pharmacists Association	General overview of new drugs, including deferasirox; no HIV-specific evidence

India Market Information

Approved indication text is not available in the licence records compiled for this report. Five of the 16 valid registrations (all single-ingredient products) are listed below.

Authorization Number	Product Name	Dosage Form	Approved Indication
Registration No. 165829	Oleptiss 90mg Tablet DT	Strip of 10 dispersible tablets	Not available
Registration No. 61741	Desifer 100 Tablet	Strip of 6 tablets	Not available
Registration No. 58643	Desirox 500 Tablet	Bottle of 30 tablets	Not available
Registration No. 62683	Defrijet FCT 180 Tablet	Strip of 10 tablets	Not available
Registration No. 1251	Asunra 400mg Tablet	Strip of 6 tablets	Not available

All dosage forms are oral.

Safety Considerations

Contraindications flagged in the knowledge graph (not label text): liver failure, liver disease, cirrhosis of liver, kidney disease, impaired renal function, thrombocytopenia, neutropenia, agranulocytosis, anemia, hyperbilirubinemia, Gilbert syndrome, active peptic ulcer disease, ocular hypertension, multiple organ dysfunction syndrome, and cancer.
Drug Interactions: 518 interactions were found in total. Major-level examples include corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone), amphotericin B (including lipid, liposomal and cholesteryl sulfate formulations), acetylsalicylic acid, mesalazine and balsalazide. Moderate-level examples include rabeprazole, pioglitazone, clarithromycin, aprepitant, saxagliptin and aluminum hydroxide.

Please also refer to the package insert for full safety information, as label warnings and contraindications were not available for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a high model score and one indirect preclinical study, with no clinical trials. Deferasirox also carries significant renal, hepatic and haematological risks, which matter in a population such as people living with HIV who often have comorbidities and take multiple medicines.

To proceed, the following is needed:

Package insert warnings and contraindications from the India Pharma source (a blocking gap for safety screening)
Mechanism of action data from DrugBank
Direct preclinical evidence (in vitro or in vivo) testing deferasirox against HIV-1
Assessment of whether iron chelation helps or harms host immunity in HIV
Review of drug-interaction and organ-toxicity risks in HIV patients on antiretroviral therapy

Other predicted indications (for reference): Chronic hepatitis C infection (score 0.9939, L4, Hold) has only an indirect iron-measurement study and a hepatotoxicity concern. Three further predictions (a rare neurodevelopmental disorder, obsolete familial combined hyperlipidemia, and dermatofibrosarcoma protuberans) have model scores only, with no trials or literature (L5, Hold).

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.